SOPHia Genetics扩大与阿斯利康的测试合作伙伴关系

2025-04-29 00:27

SOPHia Genetics (NASDAQ:SOPH) had expanded its collaboration with AstraZeneca (NASDAQ:AZN) to boost the launch of a liquid biopsy testing application.
MSK-ACCESS powered with SOPHiA DDM is "designed to detect actionable genomic alterations from a single blood draw using proprietary, state-of-the-art algorithms which analyze circulating tumor DNA (ctDNA)," according to a SOPHia press release. MSK-ACCESS was developed by Memorial Sloan Kettering Cancer Center.
"The application supports real-time cancer monitoring and treatment selection when traditional tissue biopsies are not feasible due to cost, turnaround time, insufficient tissue, or the invasiveness of the procedure," the company added.
The application supports AstraZeneca in that liquid biopsy testing can complement solid tissue testing, which can help healthcare providers determine the best treatment for a patient.

More on SOPHiA Genetics